Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lazertinib”

35 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 35 results

Testing effectiveness (Phase 2)Looking for participantsNCT06156527
What this trial is testing

Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Who this might be right for
Lazertinib
National Cancer Center, Korea 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT05601973
What this trial is testing

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Who this might be right for
Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation 60
Not applicableUnknownNCT05377788
What this trial is testing

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaEGFR T790M
Samsung Medical Center 900
Early research (Phase 1)Study completedNCT05742594
What this trial is testing

Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants

Who this might be right for
Healthy
Janssen Research & Development, LLC 64
Testing effectiveness (Phase 2)Active Not RecruitingNCT05786430
What this trial is testing

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Who this might be right for
Non-small Cell Lung Cancer
Yonsei University 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT05299125
What this trial is testing

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Metastatic Non-small Cell Lung Cancers
Latin American Cooperative Oncology Group 54
Large-scale testing (Phase 3)Active Not RecruitingNCT04487080
What this trial is testing

Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 1,074
Testing effectiveness (Phase 2)Active Not RecruitingNCT05463224
What this trial is testing

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

Who this might be right for
NSCLC
Se-Hoon Lee 150
Testing effectiveness (Phase 2)UnknownNCT06020989
What this trial is testing

Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 129
Testing effectiveness (Phase 2)Looking for participantsNCT06268210
What this trial is testing

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Yonsei University 160
Not applicableStudy completedNCT05862194
What this trial is testing

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Yuhan Corporation 534
Testing effectiveness (Phase 2)Looking for participantsNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 300
Testing effectiveness (Phase 2)Study completedNCT04965090
What this trial is testing

Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Metastatic Non Small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 43
Testing effectiveness (Phase 2)UnknownNCT05701384
What this trial is testing

Lazertinib 160mg in EGFR T790M NSCLC

Who this might be right for
Lung Cancer Stage IVEGFR T790M
Samsung Medical Center 117
Testing effectiveness (Phase 2)Looking for participantsNCT05469022
What this trial is testing

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Who this might be right for
Non Small Cell Lung Cancer
Konkuk University Medical Center 40
Testing effectiveness (Phase 2)Study completedNCT04075396
What this trial is testing

Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 29
Early research (Phase 1)Active Not RecruitingNCT04077463
What this trial is testing

Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 701
Not applicableUnknownNCT05716672
What this trial is testing

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Who this might be right for
Non-small Cell Lung Cancer
Pusan National University Hospital 200
Testing effectiveness (Phase 2)Looking for participantsNCT05338619
What this trial is testing

Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Who this might be right for
Non-small Cell Lung Cancer Stage IIIEGFR Positive Non-small Cell Lung CancerNon-squamous Non-small-cell Lung Cancer
Sung Yong Lee 77
Testing effectiveness (Phase 2)UnknownNCT05326425
What this trial is testing

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Who this might be right for
Lung Neoplasms
Jin Hyoung Kang 40
Load More Results